Product Description
Mechanisms of Action: EP3 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: Western America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Peripheral Arterial Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2006-001368-22 |
2006-001368-22 | P2 |
Completed |
Peripheral Arterial Disease |
2006-12-18 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/01/2024 |
PubMed |
Computational drug repurposing for primary hyperparathyroidism. |
|
01/01/2024 |
PubMed |
Endothelial YAP Mediates Hyperglycemia-Induced Platelet Hyperactivity and Arterial Thrombosis. |
|
07/01/2021 |
PubMed |
New drug candidates for osteosarcoma: Drug repurposing based on gene expression signature. |